Brigatinib Bests Standard of Care to Improve PFS in Advanced NSCLC
Kristie L. Kahl
Published: Tuesday, Sep 25, 2018
D. Ross Camidge, MD, PhD
Brigatinib (Alunbrig) reduced the risk of disease progression or death by more than 50% compared to crizotinib (Xalkori) in adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.
... to read the full story